MEETING RESEARCH  PRIORITIES OF THE AGENDA OF PEOPLE WITH MS

9.00 - 10.05 | MS PATHOGENESIS

Chairs: Gabriela Constantin, Claudia Verderio

9.00 - 9.20 - Giuseppe Matarese
Caloric restriction as a novel therapeutic tool to manipulate immunity and improve therapeutic potential of first line drug treatments during relapsing remitting multiple sclerosis
9.20 - 9.35 -  Francesco Annunziato
Molecular mechanisms that regulate T helper 17 lymphocytes proliferation and plasticity: implications for MS pathogenesis and progression
9.35 - 9.50  - Claudio Sette
Role of IL-1 in the modulation of the pathogenic response of human Th17 cells in MS
9.50 - 10.05 - Discussion and conclusions
Gabriela Constantin, Claudia Verderio

10.05 - 11.40 | PROGRESSIVE MS

Chairs: Roberto Furlan, Marco Salvetti, Antonio Scalfari

10.05 – 10.25 - Maria Pia Abbracchio
GPR17 ligands: where we are where we are going
10.25 – 10.40 - Stefano Carlo Previtali
Role of Jab1 and senescence in the pathogenesis of progressive MS in a mouse model
10.40 - 10.55 - Giulia Bommarito
The dynamic functional connectome in progressive MS: Novel approaches and clinical relevance
10.55 – 11.10 - Elisabetta Volpe
Study of the potential neuroprotective role of interleukin-9 in MS
11.10 - 11.25 - Raffaele d'Isa
Can non-invasive neuromodulation promote remyelination? A pilot preclinical study
11.25 - 11.40 - Discussion and conclusions
Roberto Furlan, Marco Salvetti, Antonio Scalfari

11.40 - 12.00 | COFFEE BREAK

12.00 - 13.20 | BIOMARKER OF DIAGNOSIS AND MONITORING OF THE DISEASE

Chairs: Matilde Inglese, Mara Rocca

12.00 – 12.20 - Federica Eva Esposito
Validation and functional assessment of genetic variants implicated in the response to fingolimod treatment
12.20 – 12.35 - Roberta Magliozzi
Structural and inflammatory components of cortical pathology in MS
12.35– 12.50 - Monica Biggio
A combined neurophysiological and neuroimaging approach to explore the cortico-brainstem functionality in MS
12.50 – 13.05 - Linda Chaabane
Set-up of Neural Stem cells Imaging by 19F-MRI: labeling optimization, detection limits and biocompatibility tests
13.05– 13.20 - Discussion and conclusions
Matilde Inglese, Mara Rocca

13.20 - 14.40 | LUNCH AND POSTERS PRESENTATION

14.40 - 16.45 | TOWARDS NEW TREATMENTS

Chairs: Francesco Cucca, Massimiliano Di Filippo, Giovanni Ristori

14.40 - 15.00 - Francesco Cucca
A genetic toolbox in MS drug discovery: patent development of candidate genes
15.00 - 15.15 - Roberto Furlan
Microglial microvesicles as therapeutic vector for neuroinflammation
15.15 - 15.30 - Luca Peruzzotti-Jametti
In vivo characterisation and manipulation of succinate-dependent injury in neuroinflammation
15.30 - 15.45 - Luca Muzio
Targeting neuroinflammation by REcTO proteins
15.45 - 16.00 - Alessandro Didonna
MiRNAs as novel potential tools to modulate myelination in the CNS
16.00 -16.15 - Valerio Chiurchiù
Specialized pro-resolving lipid mediators as a novel strategy to "resolve" the altered adaptive immune responses in MS
16.15 - 16.30 - Fabrizio Michetti
The S100B protein as a potential therapeutic target in MS. An in vivo study
16.30 - 16.45 - Discussion and conclusions
Francesco Cucca, Massimiliano Di Filippo, Giovanni Ristori

16.45 - 17.10 | COFFEE BREAK

17.10 - 18.15 | NEUROREHABILITATION AND QUALITY OF LIFE

Chairs: Marco Bove, Luca Prosperini

17.10 – 17.30 - Diego Centonze
The inflammatory synaptopathy as a target of exercise therapy in the fight against multiple sclerosis
17.30 - 17.45 - Andrea Manca
The effects of eccentric strength training on limb spasticity and muscle weakness in people with MS: a pilot study
17.45 - 18.00 - Carlo Trompetto
Spastic dystonia in MS: the dark side of muscle hypertonia
18.00 - 18.15 - Discussion and conclusions
Marco Bove, Luca Prosperini